Immunology Therapeutics
•260 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (260)
%
| Company | Market Cap | Price |
|---|---|---|
|
The firme’s approach is immunology-based cancer therapeutics, aligning with immunology therapeutics as a category.
|
$358.65M |
$0.25
+2.66%
|
|
Company's immunotherapies align with Immunology Therapeutics as immune-based treatments for neurodegenerative diseases.
|
$354.43M |
$3.55
+0.28%
|
|
Lead programs aim to stimulate anti-tumor immune responses, placing Replimune in Immunology Therapeutics.
|
$352.29M |
$4.67
+2.30%
|
|
The company targets immunology/inflammation (neuroinflammatory diseases) with its C1q inhibitors.
|
$340.11M |
$3.10
-4.91%
|
|
Platform modulating immune/inflammatory pathways (RASP modulators) with potential applications across immune-mediated diseases.
|
$330.02M |
$5.51
-4.67%
|
|
Immsidolimab (IL-36R antagonist) targets autoimmune inflammatory conditions, falling under Immunology Therapeutics.
|
$312.94M |
$5.31
-3.80%
|
|
Platform aims to elicit systemic anti-tumor immunity, an immunology therapeutics modality.
|
$310.14M |
$6.19
-6.07%
|
|
Immunology Therapeutics captures Alector's approach focused on immune pathways and neuroinflammation in CNS diseases.
|
$301.98M |
$3.02
-5.48%
|
|
Belapectin's immunomodulatory effects and potential to combine with checkpoint inhibitors align with Immunology Therapeutics.
|
$298.74M |
$4.72
-1.05%
|
|
Bel-sar's mechanism includes immune activation alongside tumor cell killing, aligning with immunology therapeutics.
|
$297.59M |
$5.92
-2.95%
|
|
Immutep is advancing IMP761, a LAG-3 agonist antibody for autoimmune diseases, aligning with Immunology Therapeutics.
|
$292.57M |
$2.01
-2.90%
|
|
Viaskin Peanut patch is an immunotherapy platform targeting immune modulation in pediatric peanut allergy, aligning with Immunology Therapeutics.
|
$289.50M |
$15.00
-3.29%
|
|
Kyverna targets autoimmune/immunology indications via cell therapy, fitting immunology therapeutics.
|
$286.54M |
$6.63
-5.69%
|
|
Immunotherapy approach aimed at modulating the immune system to treat cancer aligns with Immunology Therapeutics.
|
$280.13M |
$0.70
|
|
RESOLUTION program targets autoimmune diseases, aligning with immunology therapeutics.
|
$269.04M |
$1.23
-14.58%
|
|
CX-801 is a masked cytokine (interferon alpha-2b), aligning with Immunology Therapeutics.
|
$266.05M |
$3.30
+1.23%
|
|
Operates in immunology therapeutics, focusing on inflammatory pathways (NLRP3 inhibitors) and related autoimmune/neuroinflammatory indications.
|
$253.33M |
$3.56
-7.77%
|
|
Complement inhibition and immune-modulating therapies fall under immunology therapeutics.
|
$245.50M |
$4.19
-8.71%
|
|
Zura Bio's lead and pipeline assets are immunology-focused antibodies (e.g., tibulizumab targeting IL-17A and BAFF), placing the company squarely in Immunology Therapeutics.
|
$243.17M |
$3.94
+0.13%
|
|
Immunology therapeutics addressing immune-inflammatory diseases (MG, SLE) via a cell-therapy platform.
|
$241.89M |
$9.32
-8.09%
|
|
Enanta's KIT and STAT6 inhibitors represent immunology therapeutics developed as small molecules.
|
$235.57M |
$11.02
-4.26%
|
|
Lonigutamab is an immune-mediated disease therapy, aligning with Immunology Therapeutics.
|
$228.61M |
$2.27
|
|
Company focuses on immunology/immune-mediated diseases via TYK2 inhibitors and antibody therapies (Immunology Therapeutics).
|
$224.15M |
$4.29
+4.25%
|
|
Immunotherapy approach via engineered immune cells aligns with Immunology Therapeutics.
|
$213.91M |
$2.30
+5.50%
|
|
Platform focuses on immunomodulation and regulatory T cell induction to treat autoimmune/neuroinflammatory diseases.
|
$210.30M |
$2.04
-5.56%
|
|
Immunology Therapeutics: Aclaris develops therapies for immune-inflammatory diseases (e.g., atopic dermatitis, psoriasis) and autoimmune conditions.
|
$207.90M |
$1.90
-1.04%
|
|
Pipeline includes immune-modulating antibodies (e.g., CHS-114) targeting Tregs, aligning with Immunology Therapeutics.
|
$193.61M |
$1.67
-9.73%
|
|
BGE-102 inhibits the NLRP3 inflammasome, aligning with immunology therapeutics as an inflammation/immune-modulation mechanism.
|
$191.80M |
$5.35
-2.01%
|
|
Immunotherapy approach targeting cancer via immune activation, placing Genelux in Immunology Therapeutics.
|
$191.32M |
$5.07
-7.82%
|
|
GPS is WT1-targeted immunotherapy, aligning SELLAS with immunology therapeutics.
|
$190.58M |
$1.91
-1.04%
|
|
The portfolio includes immunology/immune-oncology modalities, aligning with immunology therapeutics.
|
$190.16M |
$15.54
-2.08%
|
|
Pipeline includes autoimmune/immunology therapeutics (e.g., SLE) indicating an immunology-focused program.
|
$187.42M |
$1.64
+0.31%
|
|
Eledon's direct product focus is tegoprubart, an immunology therapeutic (anti-CD40L antibody) in transplantation, placing the company squarely in Immunology Therapeutics.
|
$171.26M |
$2.86
+0.35%
|
|
Rosacea is an inflammatory/immune-mediated skin condition; Emrosi's data emphasize inflammatory lesion reduction and erythema, aligning with immunology therapeutics.
|
$169.83M |
$7.29
+0.41%
|
|
AMP platform aims to stimulate anti-tumor immune responses, aligning with immunology therapeutics.
|
$169.25M |
$10.58
-5.11%
|
|
Immunology Therapeutics covers CGEN's IO-focused therapies and immune-modulating strategies in cancer.
|
$165.64M |
$1.85
-5.13%
|
|
Leronlimab's immune-modulating mechanism and focus on tumor microenvironment align with Immunology Therapeutics.
|
$163.45M |
$0.27
+2.97%
|
|
Trogarzo (ibalizumab) is an antibody-based HIV therapy, aligning with immunology therapeutics.
|
$155.87M |
$3.39
+0.89%
|
|
TNX-1500 is an anti-CD40L monoclonal antibody, placing it in immunology therapeutics.
|
$155.21M |
$21.19
-4.46%
|
|
NKX019 targets immune-mediated autoimmune diseases, placing Nkarta in the Immunology Therapeutics space.
|
$151.14M |
$2.13
-2.29%
|
|
Avalo directly develops monoclonal antibodies targeting immune dysregulation (e.g., AVTX-9.00), placing the business in Immunology Therapeutics.
|
$145.09M |
$13.40
+3.47%
|
|
The ExacTcell/T cell therapy approach falls under Immunology Therapeutics as an immune-based treatment modality.
|
$131.50M |
$0.72
-3.36%
|
|
Immunotherapy therapeutics category, aligned with PD-L1/VEGF bispecific approach and cancer immunotherapy.
|
$126.15M |
$19.23
-8.43%
|
|
Immunology/immune-oncology modalities including multi-specific T-cell engager approaches (Switch-DARPin) and CD3 engagement.
|
$126.14M |
$3.80
+1.06%
|
|
The program targets autoimmune diseases (immunology therapeutics), aligning with immunology-focused biotech applications.
|
$123.81M |
$2.44
-1.61%
|
|
Involvement in inflammatory/chronic disease programs (e.g., ulcerative colitis) via Wnt modulation aligns with Immunology Therapeutics.
|
$117.88M |
$13.77
-1.10%
|
|
Armata develops bacteriophage-based therapeutics for bacterial infections, aligning with Immunology Therapeutics.
|
$112.92M |
$3.12
+0.65%
|
|
IPF and TNG IPs imply immunology-focused therapeutics for HIV, aligning with Immunology Therapeutics.
|
$109.82M |
$0.32
|
|
Strategic shift toward inflammatory/immune-mediated diseases aligns with Immunology Therapeutics as a core focus.
|
$109.21M |
$2.28
+1.33%
|
|
BOT/BAL are immunology/immune-oncology therapeutics, placing Agenus in Immunology Therapeutics.
|
$108.84M |
$3.97
-6.81%
|
|
Sol-Gel's focus on immuno-inflammatory dermatology conditions (e.g., dermatitis) aligns with Immunology Therapeutics.
|
$108.62M |
$38.99
-2.48%
|
|
Immunology therapeutics are implied via the company’s immunotherapy efforts, fitting the Immunology Therapeutics category.
|
$102.23M |
$2.86
+4.38%
|
|
COYA's approach centers on immunomodulation through Treg enhancement, aligning with Immunology Therapeutics.
|
$101.52M |
$6.07
-3.04%
|
|
FB102 is a therapeutic monoclonal antibody targeting CD122 for autoimmune diseases, representing Forte Biosciences' core immunology-focused drug development program.
|
$100.53M |
$15.27
+0.79%
|
|
ALXO's immune-modulating approach in cancer places it in Immunology Therapeutics.
|
$99.94M |
$1.76
-5.88%
|
|
Company's focus on IL-4/IL-13–driven inflammatory diseases, including asthma and COPD, aligns CNTB with Immunology Therapeutics.
|
$98.90M |
$1.74
-17.77%
|
|
Efzofitimod is an immunomodulatory biologic addressing inflammation and fibrosis, placing ATYR in Immunology Therapeutics.
|
$94.34M |
$1.06
-0.93%
|
|
The platform elicits targeted immune responses (cytotoxic T-cells), aligning with immunology therapeutics and immunotherapy.
|
$94.25M |
$2.57
-1.91%
|
|
Atara's portfolio centers on immunology therapeutics via cell therapy platforms.
|
$93.18M |
$15.09
-3.45%
|
|
Pelareorep acts as an immunotherapy, aligning with immunology therapeutics as a therapeutic modality in cancer.
|
$92.49M |
$1.20
-5.51%
|
|
Engages immunology therapeutics via oncology immunotherapy programs.
|
$86.33M |
$1.95
-1.52%
|
|
Company's focus is on immunology therapeutics addressing chronic inflammatory/autoimmune conditions (MS and GI), a direct fit for Immunology Therapeutics.
|
$86.09M |
$0.90
-2.61%
|
|
InflaRx develops anti-inflammatory therapies targeting the complement system, aligning with Immunology Therapeutics.
|
$81.26M |
$1.38
-4.83%
|
|
Immunotherapy therapeutics align with CNTX's approach to modulating the immune system to target cancer.
|
$81.01M |
$0.89
-1.06%
|
|
Immunology/CMV vaccine programs (e.g., Helocyte) contribute to Fortress's immunology therapeutics exposure.
|
$80.13M |
$2.71
-3.56%
|
|
Encompasses Adicet's autoimmune disease program (ADI-001) and the broader immunology therapeutic focus of the company.
|
$80.00M |
$0.97
+5.13%
|
|
Immunology-focused therapeutics via vaccines and mucosal immune responses fall under immunology therapeutics.
|
$79.22M |
$0.35
-1.41%
|
|
Immunology Therapeutics captures XBiotech's focus on immune-inflammatory therapies (dermatology, infectious disease, oncology) using antibody-based approaches.
|
$77.44M |
$2.54
-3.05%
|
|
The company has prioritized autoimmunity/immunology programs and develops immunology therapeutics, including IgM-based antibodies.
|
$76.35M |
$1.27
|
|
Develops immunology/immune-oncology therapeutics (conditioned activation cytokines and T-cell engagers).
|
$73.14M |
$1.63
-9.94%
|
|
CardiolRx's anti-inflammatory mechanism aligns with Immunology Therapeutics, a category for therapies addressing immune-inflammatory diseases.
|
$73.00M |
$1.04
-4.59%
|
|
Plinabulin modulates the immune system (GEF-H1 activation, DC maturation) and is being explored in immuno-oncology combinations, fitting Immunology Therapeutics.
|
$70.15M |
$1.74
-4.92%
|
|
Immune-mediated disease focus; IMMX seeks applications beyond AL amyloidosis, aligning with immunology therapeutics.
|
$69.69M |
$2.50
-7.41%
|
|
Immunology therapeutic focus targeting autoimmune diseases (e.g., SLE, RA) via NK cell platform in autoimmune indications.
|
$68.46M |
$2.81
-7.87%
|
|
MN-166's neuroinflammatory modulation places the company within the broader 'Immunology Therapeutics' space.
|
$62.78M |
$1.28
+3.23%
|
|
Re-Tain mastitis program uses immunology/antimicrobial peptide technology (nisin A), aligning with immunology therapeutics in biotech.
|
$61.45M |
$6.80
+1.49%
|
|
Cue Biopharma is advancing autoimmune/immunology therapeutics (CUE-401, CUE-501) via its Immuno-STAT platform.
|
$59.94M |
$0.80
-14.46%
|
|
Immunology therapeutics overlap with MindWalk's antibody discovery and immune-modulating assets.
|
$59.46M |
N/A
|
|
Immunology therapeutics category covers immuno-oncology and immune-modulating cancer therapies, aligning with Genenta's approach.
|
$59.44M |
$3.25
-2.98%
|
|
Immunology therapeutics is a broader category relevant to cancer immunotherapy programs.
|
$57.88M |
$1.57
-7.10%
|
|
OSTX's platform and programs are immunology-focused therapeutics aimed at modulating the immune response to cancer.
|
$55.91M |
$1.99
-5.24%
|
|
MiNK's platform addresses immune-mediated diseases and GvHD, reflecting an immunology/immune-modulation therapeutic focus.
|
$55.80M |
$14.00
-4.24%
|
|
Direct focus on immunology/inflammation therapeutics via lead candidate VTP-1000 and the SNAP-TI immune-tolerance platform.
|
$54.86M |
$1.36
-4.90%
|
|
Evalstotug and related assets are immunology/immune-oncology therapeutics, aligning with Immunology Therapeutics.
|
$50.68M |
$0.87
-17.38%
|
|
Immunology therapeutics and immune-oncology platforms align with an Immunology Therapeutics theme.
|
$49.11M |
$0.18
-9.80%
|
|
NK cell-based immunotherapies fall under immunology therapeutics, aligning with Celularity’s immuno-oncology/cell-therapy focus.
|
$49.10M |
$2.05
-3.76%
|
|
Immunology Therapeutics category aligns with Century's focus on immunotherapy approaches for autoimmune diseases and oncology.
|
$49.00M |
$0.57
-5.22%
|
|
DN-TNF platform modulates innate immunity (neuroinflammation focus) and fits Immunology Therapeutics.
|
$48.97M |
$2.08
-1.18%
|
|
EQ targets immune-mediated inflammatory diseases, aligning with immunology therapeutics.
|
$47.51M |
$1.45
+9.02%
|
|
Immunosynthen platform aims to immunoactivate tumors via STING agonist payloads, aligning with Immunology Therapeutics.
|
$46.06M |
$9.24
+1.43%
|
|
CalciMedica develops immunology/inflammation therapeutics (CRAC inhibition to dampen inflammation and protect tissue).
|
$44.22M |
$3.17
-6.36%
|
|
Company's immuno-oncology pipeline places it in Immunology Therapeutics within the IO space.
|
$43.64M |
$0.84
-5.31%
|
|
The company's immunotherapy approach aligns with Immunology Therapeutics, focusing on immune activation to fight cancer.
|
$43.30M |
$0.95
-5.27%
|
|
Immunology therapeutics framing due to Verrica's dermatology-focused immune-modulating approach and the oncology pipeline's immunologic mechanism.
|
$43.19M |
$4.67
+2.41%
|
|
Immuno-oncology and immune-modulating approaches align with Immunology Therapeutics.
|
$40.76M |
$1.55
+0.65%
|
|
Strategic focus on immunology therapeutics, developing targeted immune-modulating therapies for autoimmune diseases.
|
$40.22M |
$5.72
-0.35%
|
|
Immunomodulatory mechanism in oncology aligns with Immunology Therapeutics.
|
$38.30M |
$10.40
-2.07%
|
|
Immunology therapeutics alignment due to immune-modulating cancer therapy approach.
|
$36.68M |
$1.41
-9.03%
|
|
IO Biotech's platform and programs are immunology-focused, aiming to modulate the immune system in cancer.
|
$36.37M |
$0.55
-4.81%
|
|
Direct product briquilimab, a monoclonal antibody targeting the SCF/c-KIT axis for chronic urticaria, aligns with the Immunology Therapeutics category.
|
$36.05M |
$2.40
-3.23%
|
Showing page 2 of 3 (260 total stocks)
Loading industry metrics...
Loading comparison data...
